Don’t Buy Guitars (12.6.2024) Save

This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.

This week's notable citations on RheumNow.com:  

1. BMJ has published an extensive, full read review of the Advances in the management of psoriatic arthritis in adults - by Drs. Gladman and Kharouf, (great read and reference!) https://t.co/21SHvGyUZH
2. FULL READ review and overview of Axial Spondyloarthritis by Drs. Deodhar & Bittar - Dx often delayed 6-8 yrs - Sensitivity/Specificity of: HLA-B27 (50%/90%), CRP (35%/91%), Xray sacroiliitis (66%/68%) or MRI (78%/88%). Great tables, figs, Xrays &Reference!… https://t.co/MWpznXqPzq
3. Diagnostic Delays in PsA Despite the remarkable expansion of the therapeutic armamentarium for psoriatic arthritis (PsA), the MONITOR-PsA study (abstract 1456) highlights a persistent and critical issue: delays in diagnosis. https://t.co/83TeIpfutP
4. Osteoarthritis (OA) affects 53.2 million in the USA & is projected to rise significantly by 2040. Societal costs are $132 billion ($11,00 per/pt). OA is the 3rd most rapidly rising disability, behind diabetes and dementia. https://t.co/n3Rwjjsio3
5. DEA and the Department of Health and Human Services (HHS) has extended current telemedicine (TM) flexibilities through end 2025. MDs may Rx meds via TM (including narcotics) without in-office visits. https://t.co/C8lyB5feXg
6. J&J has submitted 2 supplemental BLAs applying for FDA approval of guselkumab (Tremfya) for use in juvenile plaque psoriasis & juvenile (>5-6 yrs age) psoriatic arthritis based on several phase 3 RCTs. https://t.co/dAkH219pzN
7. Another Stelara (Ustekinumab) biosimilar was FDA approved on 12/1 -- called Yesintek for the treatment of Crohn’s, Ulcerative Colitis, Psoriasis & PsA. This makes 6 FDA approved biosimilars for ustekinumab. https://t.co/ASErsKTNQ6
8. FDA has granted Rare Pediatric Disease Designation (RPDD) to a new proprietary investigational drug, 101-PCG-005, a type IA prodrug of dexamethasone targetsing CD206+ macrophages. The intended use is in systemic juvenile idiopathic arthritis (sJIA) or Still's disease . https://buff.ly/3ZqGtg5
9. Dr. Alexi Grom (video) discusses his presentation from ACR 2024, on the 80% success rate of an anti-IFN gamma mAb (emapalumab) when used in 39 Stills disease patients complicated by life-threatening macrophage activation syndrome. https://t.co/kIPmsVXkCP
10. EULAR and the Paediatric Rheumatology European Society (PReS) and FDA now view systemic juvenile idiopathic arthritis and adult-onset Still’s disease as a single entity — Still’s disease; based on overlapping tests, clinical manifestations, complications & response to biologics… https://t.co/OHfcFymdPx
11. Novel TYK2 inhibitor Zasocitinib Interest in tyrosine kinase 2 (TYK2), a member of the JAK family, is growing following the success of JAK inhibitors in treating rheumatic diseases. TYK2 is crucial for immune activation but has minimal involvement in metabolic and hematopoietic… https://t.co/eDcx4AAnAs
12. Study of 16,598 CAD pts showed in pts w/ normal hsCRP<2mg/L, increasing SUA didnt predict CV/MACE events. But if the hsCRP≥2 mg/L, increasing urate(SUA)was signif. assoc w/ increased MACE. Each 1mg incr in SUA yielded an 11% increase in MACE (adj p < 0.001)… https://t.co/9ehtOcoeBK
13. Autoantibodies in IIM: - found in over half of adult and paediatric patients with idiopathic inflammatory myopathies (IIMs), these correlate with clinical phenotypes, aiding in classification and prognosis. https://t.co/ZRXqtEec6s
14. ACR24: Rheumatology Roundup
15. Ask Cush Anything: Dr. Ephrussi – Active RA with ocular histoplasmosis.
16. RheumNow.live (register here)